Edward M. Md Kaye Sells 6,786 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) CEO Edward M. Md Kaye sold 6,786 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $88,150.14. Following the completion of the sale, the chief executive officer now directly owns 61,885 shares in the company, valued at approximately $803,886.15. This trade represents a 9.88 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Stoke Therapeutics Stock Down 2.1 %

Shares of NASDAQ:STOK traded down $0.28 on Wednesday, hitting $12.98. 283,002 shares of the company traded hands, compared to its average volume of 748,105. Stoke Therapeutics, Inc. has a 52 week low of $4.09 and a 52 week high of $17.58. The stock has a 50 day simple moving average of $12.46 and a 200-day simple moving average of $13.68. The company has a market cap of $687.55 million, a PE ratio of -6.15 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. As a group, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics in the second quarter worth $29,000. Nisa Investment Advisors LLC increased its holdings in Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after buying an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Stoke Therapeutics in the 2nd quarter worth about $123,000. Intech Investment Management LLC bought a new position in Stoke Therapeutics during the 3rd quarter valued at about $160,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares during the last quarter.

Wall Street Analyst Weigh In

STOK has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target on the stock. Finally, Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $20.83.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.